New incident report
Incident Report Number: 2014-0376
Registrant Reference Number: 2014CK056
Registrant Name (Full Legal Name no abbreviations): Bayer Inc
Address: 77 Belfield Rd
City: Toronto
Prov / State: ON
Country: Canada
Postal Code: M9W 1G6
Domestic Animal
Country: UNITED STATES
Prov / State: UNKNOWN
PMRA Registration No. PMRA Submission No. EPA Registration No. 11556-141
Product Name: K9 Advantix II(small dog)
Liquid
Yes
Units: mL
Site: Animal / Usage sur un animal domestique
Animal's Owner
Dog / Chien
pomeranian
1
Male
0.14
1.5
lbs
Skin
>1 wk <=1 mo / > 1 sem < = 1 mois
>30 min <=2 hrs / >30 min <=2 h
System
>24 hrs <=3 days / >24 h <=3 jours
Unknown
Unknown
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
Approximately 1 hour post administration the dog was vomiting.On 06Decv2013 the dog continued to vomit and was examined by a veterinarian. The dog presented with muscle tremors and loose stools. He received a bath in liquid dish soap, an injection of maropitant citrate and an unknown amount of oral maropitant citrate to be administered at home.On 08Dec2013 the dog passed away at home. A necropsy was not performed.Follow-up of 19Dec2013: On 11Dec2013 a necropsy was performed by (name) Veterinary Medical Diagnostic Laboratory and the results showed mild edema in the small intestine and colon, mild reactive lymphoid hyperplasia in the spleen, mild lipadosis in the liver and mild to minimal alveolitis observed in the lung which are non-specific changes and potential causes include aspiration or acute speitcemia. However, the presence of bacteria in the lung but lack of significant inflammation is suggestive of perimortem aspiration. There are no changes suggestive of acute toxicity in this animal. No further information expected. Case closed.
Death
Vomiting 1 hour after product application and later occurring loose stool rather unspecific in a young puppy however may reflect sensitive reaction to the product if oral uptake of the product cannot be ruled out. Even though more expected after oral ingestion as well, Permethrin has the potential to cause slight neurological disorders (e.g. tremors) in particular susceptible animals. Oedema, fatty liver and death not expected after product application as inconsistent with pharmaco-toxicolgocial product profile. Other causes are more probable in this 7 week old puppy, as autopsy report describes only non-specific changes which might be consequences of potential aspiration or acute septicemia. There are no changes suggestive of acute toxicity in this animal. Other potential reasons are, particularly as vaccination status at the time of product application is unknown and puppy was not examined by a veterinarian prior to the product application, i.e. acute infectious disease or consequence of the vomiting and loose stool as severe dehydration or electrolyte loss. Considering all aspects, a product connection is deemed unlikely